Keep weight use and diabetes use separate
When this sheet says FDA, it means the Food and Drug Administration. The agency’s U.S. work includes reviewing medicines for each specific use.
The official product information is called the medicine’s label.
Weight use
Liraglutide (Saxenda) is approved for weight treatment, based on information checked in September 2026.
For adults, its label covers obesity, or being overweight when there is also a health problem tied to weight. That use includes changes to eating and activity.
Diabetes use
The September 2026 information check confirmed approval of liraglutide (Victoza) for the blood-sugar condition type 2 diabetes.
That product is not approved for weight loss.
A generic and a compounded product are different
An approved generic copies a brand medicine and is made under FDA approval.
Approved generic
Both the weight-use group and the diabetes-use group had FDA-approved liraglutide generics as of September 2026.
Even though both contain liraglutide, the FDA does not treat a weight-use generic as a medicine the pharmacist can swap for a diabetes-use generic.
Compounded preparation
Compounding means making medicine to order in a pharmacy, by a doctor, or at a medicine-making business registered with the FDA.
Here, registered means the business has chosen to put its name on the FDA’s list; this does not approve the medicines it makes.
The approval distinction on this sheet is important: a compounded medicine is not FDA-approved, as recorded in September 2026. Quality, safety and how well it works do not receive FDA review before the medicine is sold.
As checked in September 2026, U.S. law allows a licensed pharmacy or doctor to compound for a named patient with a prescription. It also allows registered businesses to make batches. Both routes have rules they must meet.
The FDA’s recommendation is to use compounded drugs only when the patient has a medical need beyond what an approved product can meet.
Ask whether the quote is for an approved generic or a medicine made to order. For a medicine made to order, ask who makes it, which legal route they use, and how they meet its rules for your prescription.
Ask about supply and a later change
Liraglutide shots were still on the FDA’s national shortage list when it was checked in September 2026.
A national shortage listing is different from a single pharmacy running out of stock.
The FDA had also proposed leaving liraglutide off a list of ingredients allowed for batch compounding. In September 2026, this was still a proposal, with no final decision.
The proposal concerns 503B outsourcing facilities: businesses registered with the FDA that make batches of medicines, often for clinics and hospitals.
These businesses can use an ingredient on that list as one legal route to make a medicine. A separate route lets them make a medicine on the FDA’s shortage list.
The medicines they make are sterile: they contain no living germs.
The FDA inspects these businesses, and they must follow federal manufacturing quality rules.
Ask the pharmacy whether one of these businesses would make your medicine, or whether the pharmacy would make it for you.
The maker’s notice, checked in September 2026, planned the last liraglutide (Saxenda) shipments to medicine distributors for late January 2027.
That notice says the decision is not due to a safety or quality problem.
An approval record alone does not prove a pharmacy has the product in stock.
Keep these notes open while you work, or copy them before leaving the page. Nothing here sends your answers to a care service.
Check the product records
Open the notes behind this answer
A national shortage listing does not make every compounded offer legal. The shortage listing and the ingredient-list proposal are separate parts of the rules.